Solara Active Pharma Sciences posts Q4 FY25 consolidated loss at Rs. 2.10 Cr

The company has posted net profit of Rs. 0.54 crores for the Financial Year ended March 31, 2025

Neuland Laboratories posts Q4 FY25 consolidated PAT at Rs. 27.80 Cr

The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025

IOL Chemicals and Pharmaceuticals posts Q4 FY25 PAT at Rs. 31.42 Cr

IOL Chemicals and Pharmaceuticals has posted net profit of Rs.101.07 crores for the Financial Year ended March 31, 2025

Jubilant Pharmova posts Q4 FY25 consolidated PAT at Rs. 153.6 Cr

Jubilant Pharmova has posted net profit of Rs. 839.4 crores for the Financial Year ended March 31, 2025

Lupin posts consolidated Q4 FY25 PAT at Rs. 772.52 Cr

Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr

For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.

Bayer confirms 2025 targets after solid start to the year

EBITDA before special items decreases to €4.08 billion (7.4%)

Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr

PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%

Briefs: Zydus and CuraTeQ Biologics

CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA

GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr

The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025